Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

8.01EUR
11:35am EDT
Change (% chg)

€0.04 (+0.50%)
Prev Close
€7.97
Open
€7.97
Day's High
€8.06
Day's Low
€7.97
Volume
25,752
Avg. Vol
64,205
52-wk High
€11.60
52-wk Low
€7.66

Latest Key Developments (Source: Significant Developments)

Nicox Announces Research Collaboration With Ironwood Pharmaceuticals
Wednesday, 6 Jun 2018 01:30am EDT 

June 6 (Reuters) - NICOX SA ::REG-NICOX ANNOUNCES RESEARCH COLLABORATION ON NOVEL OPHTHALMIC THERAPEUTICS WITH IRONWOOD PHARMACEUTICALS.EACH COMPANY WILL BE RESPONSIBLE FOR THEIR OWN COSTS ASSOCIATED WITH ACTIVITIES CARRIED OUT AS PART OF COLLABORATION.DEPENDING ON OUTCOME, COS MAY ENTER INTO DISCUSSIONS ON NICOX'S FURTHER DEVELOPMENT OF ANY IDENTIFIED PRODUCT CANDIDATE..  Full Article

Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta
Wednesday, 14 Mar 2018 02:30am EDT 

March 14 (Reuters) - Nicox Sa ::REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA.‍INCREASE IN ROYALTIES BY 1% ON ANNUAL VYZULTA(TM) GLOBAL SALES REVENUE OVER $300 MILLION​.‍ADDITIONAL $20 MILLION IN POTENTIAL MILESTONES​.‍ROYALTIES WILL NOW BE 10% TO 16% OVER FOUR TIERS​.  Full Article

Nicox Provides 2018 Outlook And 2017 Estimated Financial Results
Tuesday, 6 Mar 2018 01:30am EST 

March 6 (Reuters) - NICOX SA ::PROVIDES 2018 OUTLOOK AND 2017 ESTIMATED FINANCIAL RESULTS.ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON.PIPELINE CANDIDATES MOVING TOWARDS CLINICAL DEVELOPMENT, WITH IND SUBMISSIONS TO THE U.S. FDA PLANNED FOR NCX 470 IN Q3 2018 AND NCX 4251 IN Q1 2019.ESTIMATED CASH POSITION OF €41.4 MILLION AS OF DECEMBER 31, 2017.IN 2018 WE ALSO EXPECT TO MAKE SIGNIFICANT ADVANCES IN OUR NO-DONATING RESEARCH PIPELINE - CEO.  Full Article

Nicox Updates on Drug Development And Outlines 2018 Activities
Tuesday, 19 Dec 2017 01:30am EST 

Dec 19 (Reuters) - NICOX SA ::RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT.ESTIMATES THAT THE U.S. PATENTS COVERING VYZULTA COULD BE EXTENDED FROM 2025 TO 2030..EXPECTS TO BEGIN RECEIVING ROYALTY REVENUE IN 2018, ALONG WITH POTENTIAL SALES AND DEVELOPMENT MILESTONES PAYMENTS‍​.NCX 470 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.NCX 4251 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.  Full Article

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article

Nicox says ‍cash balance was 47.1 million euros as of Sept. 30
Tuesday, 24 Oct 2017 01:30am EDT 

Oct 24 (Reuters) - NICOX SA ::‍CASH BALANCE OF EUR 47.1 MILLION AS OF SEPTEMBER 30, 2017​.Q3 NO REVENUE ‍​ VERSUS NO REVENUE YEAR AGO.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 01:31am EDT 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Nicox and pSivida enter strategic collaboration agreement
Tuesday, 10 Oct 2017 01:30am EDT 

Oct 10 (Reuters) - NICOX SA ::REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA.NEW INTELLECTUAL PROPERTY FROM THE COLLABORATION RELATING TO THE DRUG-DEVICE COMBINATION WILL BE JOINTLY OWNED‍​.PSIVIDA TO BE RESPONSIBLE FOR INITIAL DEVELOPMENT ACTIVITIES OF OCULAR INSERT FORMULATIONS, FOR WHICH IT WILL RECEIVE UNDISCLOSED SUMS BY NICOX‍​.  Full Article

Nicox announces licensing agreement with Eyevance
Thursday, 21 Sep 2017 01:30am EDT 

Sept 21 (Reuters) - NICOX SA ::ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES.‍TO RECEIVE $6 MILLION UPFRONT PAYMENT AND UP TO AN ADDITIONAL $42.5 MILLION IN FUTURE MILESTONES, PLUS 8-15% IN TIERED ROYALTIES​.EYEVANCE TARGETS U.S. LAUNCH OF ZERVIATE IN LATE 2018.  Full Article

Nicox H1 operating loss narrows to ‍​11.6 million euros
Friday, 8 Sep 2017 01:30am EDT 

Sept 8 (Reuters) - NICOX SA ::‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​.H1 OPERATING LOSS EUR ‍​11.6 MILLION VERSUS LOSS OF EUR 12.7 MILLION YEAR AGO.‍INVESTIGATIONAL NEW DRUG (IND) SUBMISSIONS FOR NCX 470 FOR IOP LOWERING AND NCX 4251 FOR BLEPHARITIS PLANNED FOR H1​.H1 NET LOSS OF THE YEAR EUR 12.2‍​ MILLION VERSUS LOSS OF EUR 24.2 MILLION YEAR AGO.‍BAUSCH + LOMB RESPONDED TO VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% COMPLETE RESPONSE LETTER (CRL) RECEIVED FROM FDA​.REPORTS H1 NO REVENUE VERSUS EUR 9,000 YEAR AGO.NET LOSS FROM CONTINUING OPERATIONS EUR 12.2 MILLION AS OF JUNE 30, 2017, VERSUS NET LOSS OF EUR 12.9 YEAR AGO.‍CASH, CASH EQUIVALENTS OF EUR 20.4 MILLION AS OF JUNE 30, 2017, COMPARED TO EUR 28.9 MILLION ON DECEMBER 31, 2016​.  Full Article

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017